These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 32590026)

  • 1. LGALS1 acts as a pro-survival molecule in AML.
    Ruvolo PP; Ma H; Ruvolo VR; Zhang X; Post SM; Andreeff M
    Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118785. PubMed ID: 32590026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
    Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
    Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
    Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
    Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectins as regulators of cell survival in the leukemia niche.
    Ruvolo PP
    Adv Biol Regul; 2019 Jan; 71():41-54. PubMed ID: 30245264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway.
    Shi J; Dai R; Chen Y; Guo H; Han Y; Zhang Y
    Hematol Oncol; 2019 Oct; 37(4):474-482. PubMed ID: 31325181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.
    Andresen V; Erikstein BS; Mukherjee H; Sulen A; Popa M; Sørnes S; Reikvam H; Chan KP; Hovland R; McCormack E; Bruserud Ø; Myers AG; Gjertsen BT
    Cell Death Dis; 2016 Dec; 7(12):e2497. PubMed ID: 27906185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells.
    Qin H; Peng M; Cheng J; Wang Z; Cui Y; Huang Y; Gui Y; Sun Y; Xiang W; Huang X; Huang T; Wang L; Chen J; Hou Y
    Cell Death Dis; 2024 Jul; 15(7):482. PubMed ID: 38965225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
    Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
    J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
    Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
    Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin.
    Quentmeier H; Martelli MP; Dirks WG; Bolli N; Liso A; Macleod RA; Nicoletti I; Mannucci R; Pucciarini A; Bigerna B; Martelli MF; Mecucci C; Drexler HG; Falini B
    Leukemia; 2005 Oct; 19(10):1760-7. PubMed ID: 16079892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
    Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
    J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.
    Carter BZ; Mak DH; Shi Y; Fidler JM; Chen R; Ling X; Plunkett W; Andreeff M
    Leukemia; 2012 Mar; 26(3):443-50. PubMed ID: 21904380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
    De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
    Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
    Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
    Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective induction of TP53I3/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3.
    Voltan R; Secchiero P; Corallini F; Zauli G
    Mol Carcinog; 2014 Jun; 53(6):498-504. PubMed ID: 23192887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia.
    Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M
    Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CITED2 affects leukemic cell survival by interfering with p53 activation.
    Mattes K; Berger G; Geugien M; Vellenga E; Schepers H
    Cell Death Dis; 2017 Oct; 8(10):e3132. PubMed ID: 29072699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IRF9-SIRT1-P53 axis is involved in the growth of human acute myeloid leukemia.
    Tian WL; Guo R; Wang F; Jiang ZX; Tang P; Huang YM; Sun L
    Exp Cell Res; 2018 Apr; 365(2):185-193. PubMed ID: 29501566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.